ClinicalTrials.gg
CompletedNCT04993807Updated Oct 15, 2026Results posted

Data-driven SDM to Reduce Symptom Burden in AF

An interventional study of Shared decision-making tool in Atrial Fibrillation and Patient Engagement, sponsored by Columbia University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Columbia University · Not applicable, Interventional, and Other

How we know

Updated Oct 15, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
431st of 679
75 · median 127
Started
2024
with 53 others
No phase
405 of 993
67 open now
Registered
733rd of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 431st largest by enrollment of the 679 interventional ones that give a count, is one of 54 that started in 2024, is one of 405 with no phase, and was the 733rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

This study is a single-group feasibility study evaluating decision aid visualizations which display common post-ablation symptom patterns as a tool for shared decision-making. The specific aim of the clinical trial is to evaluate the feasibility of putting the visualizations into clinical practice (n=75). The hypothesis is that patients will report low decisional conflict and decision regret and high satisfaction with their decision about whether to undergo an ablation or not.

Read the detailed description

Atrial fibrillation (AF) is the most common heart rhythm disorder, and nearly 90% of patients experience symptoms such as shortness of breath that directly impair their health-related quality of life (HRQoL). Catheter ablation is a minimally invasive, surgical procedure that is routinely performed to treat AF and associated symptoms with the goal of improving HRQOL, but also carries potentially serious risks. Shared decision-making (SDM), in which treatment decisions are aligned based on high quality evidence and patient values and goals of care, is a widely encouraged practice for navigating complex healthcare decisions such as these. However, SDM around rhythm and symptom management does not routinely occur due to a lack of detailed evidence about symptom improvement post-ablation, and a lack of decision aids to communicate evidence to patients. The overarching goal of this award is to create an interactive patient decision aid composed of established evidence from clinical trials together with novel "real world" evidence about symptom improvement post ablation mined from electronic health records (EHRs).

The investigators propose to use "real-world evidence" drawn from electronic health records (EHRs) to characterize post-ablation symptom patterns, and display them in decision-aid visualizations to support shared decision-making (SDM). In this project, the investigators will first use natural language processing (NLP) and machine learning (ML) to extract and analyze symptom data from narrative notes in EHRs. The investigators will also employ a rigorous, user-centered design protocol created during the Principal Investigator's post-doctoral work to develop decision-aid visualizations. In the clinical trial, the investigators will evaluate the feasibility of implementing these interactive decision-aid visualizations in clinical practice.

03

Conditions studied

  • Atrial Fibrillation
  • Patient Engagement

Keywords

  • Shared Decision-Making (SDM)
  • Symptom Burden
  • Decisional Conflict
  • Decision Regret
  • Decision Satisfaction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of paroxysmal AF according to International Classification of Diseases, Tenth Revision (ICD-10)
  • Scheduled consultation at NewYork-Presbyterian Hospital (NYP) to discuss catheter ablation
  • Symptomatic AF at baseline
  • Age 18 years and older
  • Able to read and speak English
  • Willing/able to provide

Exclusion criteria

Exclusion Criteria:

  • Asymptomatic AF
  • Severe cognitive impairment
  • Major psychiatric illness
  • Concomitant terminal illness that would preclude participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Shared decision-making tool

    Participants in this arm will view a shared decision-making tool while they are undergoing consultation to have an atrial fibrillation ablation.

    Other: Shared decision-making tool

Interventions

  • OtherShared decision-making tool

    Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.

06

What researchers measure

Primary outcomes

  1. Baseline Decisional Conflict Assessed Using the Decisional Conflict Scale

    Conflict about the decision to undergo atrial fibrillation will be assessed using the Decisional Conflict Scale on a scale of 0 (no decisional conflict) to 100 (extremely high decisional conflict).

    Time frame: Baseline

  2. Two Week Decisional Conflict Assessed Using the Decisional Conflict Scale

    Conflict about the decision to undergo atrial fibrillation will be assessed using the Decisional Conflict Scale on a scale of 0 (no decisional conflict) to 100 (extremely high decisional conflict).

    Time frame: 2 weeks

  3. Baseline Decision Self-Efficacy Score Assessed Using the Decision Self-Efficacy Scale

    The Decision Self-Efficacy Scale ranges from 0-100; higher indicates more self-efficacy.

    Time frame: Baseline

  4. Two Week Decision Self-efficacy Assessed Using the Decisional Self-Efficacy Scale

    The Decision Self-Efficacy Scale ranges from 0-100; higher indicates more self-efficacy.

    Time frame: 2 weeks

Secondary outcomes

  1. Post-ablation Symptom Burden Assessed Using the Atrial Fibrillation Severity Scale (AFSS)

    The severity of atrial fibrillation symptoms after an ablation will be assessed using the AFSS on a scale of 0 (no symptom burden) to 35 (extremely high symptom burden).

    Time frame: 12 weeks

  2. Post-ablation Health-related Quality of Life Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire

    Health-related quality of life after an ablation will be assessed using the AFEQT on a scale of 0 (complete disability) to 100 (high quality of life).

    Time frame: 12 weeks

07

Results

Posted Oct 15, 2026

Participant flow

Participant flow — Overall Study
MilestonePilot Cohort
Started75
Completed58
Not completed17
Withdrew: Lost to follow-up17

Outcome measures

PrimaryBaseline Decisional Conflict Assessed Using the Decisional Conflict Scale

Conflict about the decision to undergo atrial fibrillation will be assessed using the Decisional Conflict Scale on a scale of 0 (no decisional conflict) to 100 (extremely high decisional conflict).

Time frame:
Baseline
Reported as:
Mean · Score
Baseline Decisional Conflict Assessed Using the Decisional Conflict Scale
ScoreIntervention Arm
Baseline Decisional Conflict Assessed Using the Decisional Conflict Scale25.1 ± 18.0
PrimaryTwo Week Decisional Conflict Assessed Using the Decisional Conflict Scale

Conflict about the decision to undergo atrial fibrillation will be assessed using the Decisional Conflict Scale on a scale of 0 (no decisional conflict) to 100 (extremely high decisional conflict).

Time frame:
2 weeks
Reported as:
Mean · Score
Two Week Decisional Conflict Assessed Using the Decisional Conflict Scale
ScoreIntervention Arm
Two Week Decisional Conflict Assessed Using the Decisional Conflict Scale30.3 ± 25.5
PrimaryBaseline Decision Self-Efficacy Score Assessed Using the Decision Self-Efficacy Scale

The Decision Self-Efficacy Scale ranges from 0-100; higher indicates more self-efficacy.

Time frame:
Baseline
Reported as:
Mean · Score
Baseline Decision Self-Efficacy Score Assessed Using the Decision Self-Efficacy Scale
ScorePilot Cohort
Baseline Decision Self-Efficacy Score Assessed Using the Decision Self-Efficacy Scale40.7 ± 11.3
SecondaryPost-ablation Symptom Burden Assessed Using the Atrial Fibrillation Severity Scale (AFSS)

The severity of atrial fibrillation symptoms after an ablation will be assessed using the AFSS on a scale of 0 (no symptom burden) to 35 (extremely high symptom burden).

Time frame:
12 weeks
Reported as:
Mean · Score
Post-ablation Symptom Burden Assessed Using the Atrial Fibrillation Severity Scale (AFSS)
ScorePilot Cohort
Post-ablation Symptom Burden Assessed Using the Atrial Fibrillation Severity Scale (AFSS)4.60 ± 5.27
SecondaryPost-ablation Health-related Quality of Life Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire

Health-related quality of life after an ablation will be assessed using the AFEQT on a scale of 0 (complete disability) to 100 (high quality of life).

Time frame:
12 weeks
Reported as:
Mean · Score
Post-ablation Health-related Quality of Life Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire
ScorePilot Cohort
Post-ablation Health-related Quality of Life Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire80.86 ± 15.61
PrimaryTwo Week Decision Self-efficacy Assessed Using the Decisional Self-Efficacy Scale

The Decision Self-Efficacy Scale ranges from 0-100; higher indicates more self-efficacy.

Time frame:
2 weeks
Reported as:
Mean · Score
Two Week Decision Self-efficacy Assessed Using the Decisional Self-Efficacy Scale
ScorePilot Cohort
Two Week Decision Self-efficacy Assessed Using the Decisional Self-Efficacy Scale38.9 ± 9.8

Adverse events

Collected over From enrollment up to 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pilot Cohort0/75 (0%)0/75 (0%)0/75 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pilot Cohort
Mean67.1 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Pilot Cohort
Female25
Male50
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pilot Cohort
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American7
White62
More than one race0
Unknown or Not Reported4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pilot Cohort
Hispanic or Latino2
Not Hispanic or Latino66
Unknown or Not Reported7
Decisional Conflict Score
Decisional Conflict Score(Score)Pilot Cohort
Mean25.1 ± 18.0
08

Study locations

2 sites
  • Weill Cornell Medicine
    New York, New York 07030, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
09

References and documents

Publications

  • Reading Turchioe M, Shamnath A, Slotwiner D, Zhao Y, Saluja D, Goldbarg S, Kim J, Varosy P, Biviano A. Evaluating a digital decision aid for atrial fibrillation rhythm control in a hybrid implementation-effectiveness trial. NPJ Digit Med. 2026 Mar 6;9(1):326. doi: 10.1038/s41746-026-02405-y. PubMed 41792400 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) will be available to other researchers upon reasonable request after Data Use Agreements have been executed.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 3 years and ending 5 years following publication.

Access criteria: Researchers who provide a methodologically sound proposal and have completed Data Use Agreements.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jun 2025, 14 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 14 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2021
First posted
Aug 6, 2021
StartActual
Mar 25, 2024
Primary completionActual
Jun 20, 2025
CompletionActual
Aug 20, 2025
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Primary outcomes
3 edited, 1 added
What changed in the outcomes
  • EditedBaseline Decisional conflict assessed usingConflict Assessed Using the Decisional Conflict ScaleTime frame: Baseline
  • EditedDecision regret assessed usingTwo Week Decisional Conflict Assessed Using the Decisional RegretConflict ScaleTime frame: 12 weeks → 2 weeks
  • EditedBaseline Decision satisfaction assessed usingSelf-Efficacy Score Assessed Using the Satisfaction with Decision Self-Efficacy ScaleTime frame: 12 weeks → Baseline
  • AddedTwo Week Decision Self-efficacy Assessed Using the Decisional Self-Efficacy ScaleTime frame: 2 weeks
Oct 15, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedPost-ablation symptom burden assessed usingSymptom Burden Assessed Using the Atrial Fibrillation severitySeverity Scale (AFSS)Time frame: 12 weeks
  • EditedPost-ablation healthHealth-related qualityQuality of life assessed usingLife Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaireQuestionnaireTime frame: 12 weeks
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Primary outcomes 3 edited, 1 added
    What changed in the outcomes
    • EditedBaseline Decisional conflict assessed usingConflict Assessed Using the Decisional Conflict ScaleTime frame: Baseline
    • EditedDecision regret assessed usingTwo Week Decisional Conflict Assessed Using the Decisional RegretConflict ScaleTime frame: 12 weeks → 2 weeks
    • EditedBaseline Decision satisfaction assessed usingSelf-Efficacy Score Assessed Using the Satisfaction with Decision Self-Efficacy ScaleTime frame: 12 weeks → Baseline
    • AddedTwo Week Decision Self-efficacy Assessed Using the Decisional Self-Efficacy ScaleTime frame: 2 weeks
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedPost-ablation symptom burden assessed usingSymptom Burden Assessed Using the Atrial Fibrillation severitySeverity Scale (AFSS)Time frame: 12 weeks
    • EditedPost-ablation healthHealth-related qualityQuality of life assessed usingLife Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaireQuestionnaireTime frame: 12 weeks
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04993807
Responsible party
Meghan Turchioe (Assistant Professor of Nursing, Columbia University) — Principal investigator
First posted
Aug 6, 2021
Start date
Mar 25, 2024
Primary completion
Jun 20, 2025
Completion
Aug 20, 2025
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Meghan Reading Turchioe, PhD, MPH, RN
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion